Advertisement
The conference, entitled "Evaluate the Legislative, Economic andScientific Implications of the Industry Debate on: Biosimilars and Follow-OnBiologics," will be held at the Doubletree Hotel Crystal City in Arlington,Virginia, and will run from Monday, April 28 through Tuesday, April 29. Theconference will bring together corporate, regulatory, financial, and legalexperts in the field of FOBs. Dr. Allan will discuss Insmed's comprehensiveportfolio of FOBs, and the Company's initiatives aimed at helping garnerawareness of the need to establish a regulatory pathway for FOBs in the U.S.so that patients can be provided greater choice through access to theseimportant medicines. His presentation will be entitled, "The Promise ofFollow-On Biologics: The Need to Match Policy with Capability and Demand."Dr. Allan's presentation will be available on Insmed's website atwww.insmed.com following the conference.
Advertisement
The Follow-on Biologics Market
According to published reports, an estimated $10 billion worth of biologicdrugs are expected to come off patent by 2010, with an additional $10 billionby 2015. FOBs would provide safe and effective therapies at a reduced costfollowing the expiration of the original product's patent. A recenteconometric study commissioned by Insmed and conducted by economist Dr. RobertJ. Shapiro, former Under Secretary of Commerce in the Clinton Administration,found that "...generic versions of the top 12 categories of biologictreatments with patent protections that have expired or that are due to expirein the near future could save Americans $67 billion to $108 billion over 10years and $236 billion to $378 billion over 20 years."
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein processdevelopment and manufacturing experience and a proprietary protein platformaimed at niche markets with unmet medical needs. For more information, pleasevisit www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuantto provisions of Section 21E of the Securities Exchange Act of 1934. Investorsare cautioned that such statements in this release, including statementsrelating to planned clinical study design, regulatory and business strategies,plans and objectives of management and growth opportunities for existing orproposed products, constitute forward-looking statements which involve risksand uncertainties that could cause actual results to differ materially fromthose anticipated by the forward-looking statements. The risks anduncertainties include, without limitation, risks that product candidates mayfail in the clinic or may not be successfully marketed or manufactured, we maylack financial resources to complete development of product candidates, theFDA may interpret the results of studies differently than us, competingproducts may be more successful, demand for new pharmaceutical products maydecrease, the biopharmaceutical industry may experience negative markettrends, our entrance into the follow on biologics market may be unsuccessful,our common stock could be delisted from the Nasdaq Capital Market and otherrisks and challenges detailed in our filings with the U.S. Securities andExchange Commission, including our Annual Report on Form 10-K for the yearended December 31, 2007. Readers are cautioned not to place undue reliance onany forward-looking statements which speak only as of the date of thisrelease. We undertake no obligation to publicly release the results of anyrevisions to these forward-looking statements that m